Open for inclusion

A phase 1B study to evaluate safety anf clinical activity of pembrolozumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for trible negative breast cancer

Cancer type: Breast cancer

Phase: I

Principal Investigator: Mattson Johanna

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02622074?term=2015-002405-11&rank=1